Business
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product
About this update from Exelixis, Inc.
[{"type":"text","content":"\n– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 –\n\n\n– Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion –\n\n\n– Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12th at 5:15 p.m. PT / 8:15 p.m. ET –\n\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nExelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2025, provided financial guidance for fiscal year 2026 and delivered an update on its business. Exelixis anticipates 2026 will be a significant year of clinical, regulatory and commercial progress as the company grows its current cabozantinib business, works toward building a potential second commercial franchise with zanzalintinib and moves its earlier stage pipeline forward. As outlined at its December 2025 R&D Day, the company seeks to leverage its diverse pipeline and key clinical collaborations to build next-generation oncology franchises that can improve standards of care for patients with cancer.\n\n\nPreliminary Fiscal Year 2025 Financial Results & 2026 Financial Guidance\n\n\nExelixis is providing the following preliminary unaudited 2025 financial results and financial guidance for 2026. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of zanzalintinib for the treatment of patients with previously treated metastatic colorectal cancer (CRC). The U.S. Food and Drug Administration (FDA) is currently reviewing Exelixis' New Drug Application (NDA) for this proposed indication, when used in combination with atezolizumab (Tecentriq®).\n\n\n\n\n \n\n\n\n\n\n\nFiscal Year 2025\n\n\n\n\n\n\nFiscal Year 2026 Guidance\n\n\n\n\n\n\n\n\nTotal revenues\n\n\n\n\n\n\n~ $2.320 billion\n\n\n\n\n\n\n$2.525 billion - $2.625 billion\n\n\n\n\n\n\n\n\nNet product revenues\n\n\n\n\n\n\n~ $2.123 billion\n\n\n\n\n\n\n$2.325 billion - $2.425 billion(1)\n\n\n\n\n\n\n\n\nCost of goods sold, % of net product revenues\n\n\n\n\n\n\n~ 3.7%\n\n\n\n\n\n\n3.5% - 4.5%\n\n\n\n\n\n\n\n\nResearch and development expenses\n\n\n\n\n\n\n~ $825 million(2)\n\n\n\n\n\n\n$875 million - $925 million(3)\n\n\n\n\n\n\n\n\nSelling, general and administrative expenses\n\n...